The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The PI3K/Akt/mTOR pathway is crucial in breast cancer oncogenesis, with specific aberrations driving distinct molecular subtypes.
• Previous PI3K pathway inhibitors faced challenges in pharmacokinetics, tolerability, and efficacy, limiting their clinical utility.
• A need exists for improved PI3K inhibitors for effective breast cancer treatment regimens.

Purpose of the Study:

• To review promising new-generation PI3K pathway inhibitors for breast cancer.
• To present preclinical and early clinical evidence for these novel agents.
• To examine challenges in PI3K inhibitor development and explore combination strategies.

Main Methods:

• Literature review of preclinical and clinical studies on novel PI3K pathway inhibitors.
• Analysis of ongoing clinical trials involving these agents in breast cancer patients.
• Examination of research on combination therapies, including immunotherapies and epigenetic agents.

Main Results:

• New PI3K inhibitors demonstrate potential for more robust results compared to earlier drugs.
• Challenges persist in using PI3K inhibitors as monotherapies due to development hurdles.
• Combination therapies involving PI3K inhibitors are an active and dynamic area of research.

Conclusions:

• Next-generation PI3K pathway inhibitors represent a promising avenue for breast cancer therapy.
• Overcoming limitations of monotherapy requires further investigation into combination strategies.
• Exploring combinations with immunotherapies and epigenetic agents may enhance treatment efficacy.